Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Triple-Negative Breast Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Atezolizumab
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Biological: PD1 Inhibitor

First Posted Date: 2020-11-20

Last Posted Date: 2023-08-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04639245

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

FT819 in Subjects With B-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Lymphoma, B-Cell
Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions: Drug: FT819
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2020-11-16

Last Posted Date: 2024-08-02

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 54

Registration Number: NCT04629729

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 14 locations

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Early Phase 1

Conditions: Adult B Acute Lymphoblastic Leukemia

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD19+CD22 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626726

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Early Phase 1

Conditions: Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD 19+22
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626765

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Early Phase 1

Conditions: Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD19+CD22 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 100

Registration Number: NCT04626739

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Early Phase 1

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: BCMA CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626752

Locations: 🇨🇳
the Second Hospital of HeBei Medical University (HBMU), Shijiazhuang, Hebei, China

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: AML, Adult
Acute Myeloid Leukemia
Multiple Myeloma
Myeloma

Interventions: Drug: FT538
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Daratumumab
Drug: Elotuzumab

First Posted Date: 2020-11-04

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 42

Registration Number: NCT04614636

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Relapse/Refractory Multiple Myeloma

Interventions: Biological: CYAD-211
Drug: Endoxan
Drug: Fludara

First Posted Date: 2020-11-03

Last Posted Date: 2023-08-31

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 18

Registration Number: NCT04613557

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇺🇸
Nyu Langone Hospitals, New York, New York, United States

and more 2 locations

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1

Terminated

Conditions: Metastatic Ovarian Cancer
Metastatic Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Cyclophosphamid
Drug: Ipilimumab
Drug: Fludarabine Phosphate
Biological: Tumor Infiltrating Lymphocytes infusion
Drug: Nivolumab
Drug: Relatlimab

First Posted Date: 2020-11-02

Last Posted Date: 2024-07-19

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 5

Registration Number: NCT04611126

Locations: 🇩🇰
National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark

Axi-cel in CNS Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma Cns
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-10-29

Last Posted Date: 2024-06-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT04608487

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy